NIKKEI 225
38,170.48 +618.32 (+1.65%) HANG SENG
16,993.28 +164.35 (+0.98%) CRUDE OIL
83.28 -0.08 (-0.10%) GOLD FUTURES
2,331.40 -10.70 (-0.46%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,590.73 -39.74 (-0.07%)
Aprea Therapeutics, Inc. (APRE)
After hours:
| Previous close | 5.16 |
| Open | 5.14 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.14 - 5.62 |
| 52-week range | 2.78 - 8.85 |
| Volume | |
| Avg. volume | 33,480 |
| Market cap | 29.16M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.95 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.67 |
GlobeNewswireAprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented ATRN-119, a novel macrocyclic ATR inhibitor, continues to appear safe and well tolerated with no Dose Limiting Toxicities observed in ongoing Phase 1/2a study; preliminary signs of clinical benefit reported; e
- GlobeNewswire
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in H1 2024. $21.6 million in cash and cash equivalents as of December 31, 2023 Private placement financing in March 2024 raised upfront gross proceeds of approximately $16 million DOYLESTOW
- GlobeNewswire
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0 million in potential warrant exercise proceeds for an aggregate of up to $34.0 million in total gross proceeds DOYLESTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on
